Navigation Links
Einstein to develop anti-HIV drug delivery system
Date:10/2/2009

October 2, 2009 (BRONX, NY) The National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a four-year, $7.2 million grant to develop a microbicide-releasing vaginal ring to prevent HIV transmission.

"While condoms are excellent at preventing the transmission of HIV, it's often difficult for women to negotiate their use," says principal investigator Betsy C. Herold, M.D., professor of pediatrics, of microbiology & immunology, and of obstetrics & gynecology and women's health at Einstein. "It's imperative that women have alternative strategies available to protect their own health. Our belief is that an intravaginal ring that delivers a combination of drugs is the best strategy."

Vaginal rings are soft, plastic, doughnut-shaped devices designed to provide controlled release of drugs to the vagina over extended periods. At present, there are several models available for delivering contraceptives, but none for microbicides.

Dr. Herold and her colleagues will evaluate several anti-HIV microbicides, ultimately aiming for a two-drug combination. "Over the last decade, we've learned that when you expose HIV to a single drug, you make it easier to select for resistance," she says. "So, we are trying to target HIV infection at two different steps very early in its life cycle, which should prevent the establishment of any infection."

One of the drugs to be evaluated is tenofovir, which blocks reverse transcriptase, an enzyme crucial to HIV reproduction. Tenofovir is used currently as an oral systemic therapy against HIV, but it has also shown promise as a topical microbicide. The team will also test the efficacy of two so-called fusion inhibitors, including maraviroc and PIE12-trimer, which block the virus from entering target immune cells by different mechanisms.

The team will pay particular attention to choosing microbicides that preserve natural vaginal defenses against HIV. In recent years, supposedly safe microbicides were found to make women more susceptible to HIV infection. As Dr. Herold demonstrated in an earlier study, (http://www.einstein.yu.edu/home/news.asp?id=381) these microbicides most likely failed because they disrupted the vagina's epithelial lining, which provides a protective barrier against infection.

"We want to preserve that protective barrier while adding drugs that will be at the right place at the right time when the virus presents," says Dr. Herold. "That is why a ring, which can provide sustained delivery of the microbicide over three to four weeks, would be ideal. People wouldn't have to remember to use it, which is a problem with gels and pills. Also, we don't know if oral medications will get to the right place some drugs get into the genital tract well, but some don't." The ring could be replaced monthly without a doctor's supervision.

The microbicides will be incorporated into vaginal ring under development at the University of Utah, Department of Bioengineering, which is collaborating on the study.

"We've deliberately chosen to focus on drugs that have already been approved for systemic use or are far along in the regulatory process. This should shorten the time it takes to begin clinical trials. We know that every day that goes by, more people are getting infected with HIV," says Dr. Herold. The researchers hope to start Phase I clinical testing within the next four years.

The need for a microbicide-releasing vaginal ring is especially urgent in sub-Saharan Africa, where the infection rate among 15 to 49 year-olds exceeds 23 percent in some countries. AIDS is the leading cause of death in sub-Saharan Africa and women account for six out of ten of those living with HIV. "But this is not just a global health problem," says Dr. Herold. "This is a problem here in the U.S. The rates of HIV in certain regions in this country parallel the rates in many areas of developing world."

According to the Centers for Disease Control and Prevention, the national infection rate in the United States is 1 percent; in D.C., it is 3 percent, and in the Bronx, 1.7 percent. While men still have higher rates of infection than women in the U.S., AIDS is a common killer for women ranking third after cancer and heart disease. As of 2007, there were 9,000 women with HIV/AIDS living in the Bronx.


'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert  

Related biology news :

1. Einstein scientists move closer to a safer anthrax vaccine
2. Einstein researchers devise a fast and sensitive way to detect ricin
3. NIH funds research center for womens reproductive health at Einstein
4. Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time
5. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
6. Einstein scientists receive $10 million NIH grant
7. Einstein researchers develop technique to count messages made by single genes
8. Einstein researchers develop a new way to study how breast cancer spreads
9. In scientific first, Einstein researchers correct decline in organ function associated with old age
10. Feinstein researchers develop new genetic method and identify novel genes for schizophrenia
11. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Einstein to develop anti-HIV drug delivery system
(Date:1/11/2017)... 11, 2017  Michael Johnson, co-founder of Visikol Inc. a company ... has been named to the elite "Forbes 30 Under 30" list ... 600 people in 20 fields nationwide to be recognized as a ... applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... CAMBRIDGE, Mass. , Jan. 21, 2017   ... of novel compounds designed to target cancer stemness pathways, ... lead investigational compound, napabucasin, at the 2017 American Society ... San Francisco . In ... administered investigational agent designed to inhibit cancer stemness pathways ...
(Date:1/20/2017)... , January 20, 2017 ... market conditions have influenced the most recent performances of ... Inc. (NASDAQ: RGLS ), Abeona Therapeutics Inc. ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... report by Grand View Research, global Biotech market size is expected ...
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... -- Research and Markets has announced the addition of ... Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" report ... ... projected to reach $15,737 million by 2022 from $6,521 in 2015, ... Omic technologies segment accounted for more than half of ...
Breaking Biology Technology: